X

Drug Profile

UBX 306

Alternative Names: UBX-306

Latest Information Update: 22 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ubix Therapeutics
Developer NeoImmuneTech
Class Antineoplastics
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Cancer

Most Recent Events

21 Feb 2024 Early research in Cancer in USA (unspecified route) prior to February 2024 (Ubix Therapeutics pipeline, February 2024)
23 Mar 2020 NeoImmuneTech enteres into an exclusive licensing agreement with Ubix Therapeutics to develop up to three drug candidates utilizing UBIX’s Degraducer® platform technology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com